Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.

Journal Article (Journal Article;Review)

Glycoprotein (GP) IIb/IIIa inhibitors are potent antiplatelet agents and represent an exciting breakthrough in the treatment of acute coronary syndromes. However, their safety and cost-effectiveness require further investigation, and more information on risk stratification is needed to clarify which patients benefit the most from empiric use of these agents.

Full Text

Duke Authors

Cited Authors

  • Roe, MT; Sapp, SK; Lincoff, AM

Published Date

  • February 2000

Published In

Volume / Issue

  • 67 / 2

Start / End Page

  • 131 - 140

PubMed ID

  • 10680279

International Standard Serial Number (ISSN)

  • 0891-1150

Digital Object Identifier (DOI)

  • 10.3949/ccjm.67.2.131


  • eng

Conference Location

  • United States